+++
title = 'Healthcare Global Enterprises Ltd - Mar 2025 Earnings Call Transcript Analysis'
date = 2025-03-06 11:57:54
readTime = true
tags = ["Healthcare Global Enterprises Ltd.", "HCG", "Hospitals & Clinics", "Healthcare","Small Cap", "Earnings Call"]
showTags = true
toc = true
+++



## Earnings Call Transcript Analysis Report
## HCG Q3 FY'25 Earnings Call Analysis

### Financial Performance

*   **Key Financial Metrics:**
    *   **Revenue:** Q3 FY '25: INR 559 crores (highest ever quarterly revenue), 19% YoY growth. 9 Months FY'25: INR 1,638 crores, 16% YoY growth.
    *   **Adjusted EBITDA:** Q3 FY '25: INR 92.3 crores, 15% YoY growth.
    *   **Adjusted EBITDA Margin:** Q3 FY '25: 16.5%.
    *   **PAT Growth:** 23% YoY.
    *   **MG Hospital (Vizag) Revenue:** INR 25 crores, with a 24% margin.
    *   **ARPOB (Average Revenue Per Occupied Bed):** Grew by 3.5%, standing at INR 44,284. Established centers: INR 42,798 (2.8% growth). Emerging centers: INR 66,000 (12.3% growth).
    *   **Effective Tax Rate:** 3% for a 9-month period.
    *   **South Mumbai Center Losses:** INR 10-12 Crores for FY'25
*   **Comparison with Previous Periods:**
    *   Q3 revenue showed a 19% YoY increase.
    *   9-month revenue showed a 16% YoY increase.
    *   Adjusted EBITDA grew by 15% YoY in Q3.
    *   Bed occupancy improved from 52% in Q3 FY24 to 55% in Q3 FY25
*   **Revised Guidance/Forecasts:**
    *   Expect stronger growth in Q4 FY '25 (revenue and EBITDA).
    *   Expect EBITDA margin to expand by 1% to 1.5% in the next financial year compared to FY25.
    *   South Mumbai center expected to break even by Q1 of next financial year.
    *   Capex for the year estimated to be INR 275 crores, with INR 172 crores already deployed.
    *   Maintenance Capex to be around 100cr per annum.
*   **Areas of Growth/Decline:**
    *   **Growth:**
        *   Oncology business (post MG Hospital Vizag acquisition): 24% growth.
        *   Emerging centers: 25% YoY revenue growth.
        *   Kolkata centers: 40% growth.
        *   South Mumbai center: 28% growth.
        *   Chemotherapy sessions: 19% growth.
    *   Established centers: 20% revenue growth, 14% EBITDA growth.
    *   Core HCG Centers (excluding Milann): 21% revenue increase. 16% EBITDA growth, with a 20% EBITDA margin
    *   Oncology Centers (excluding Milann, multispeciality, and MG Vizag): 18% revenue increase, 14% EBITDA growth, 21% margin.
    *   **Decline:**
        *   Milann revenue continues to decline, although management is optimistic about a turnaround.

### Strategic Initiatives & Business Updates

*   **Major Strategic Announcements:**
    *   **Ownership Change:** CVC sold a majority stake to KKR. KKR is expected to hold 54-77% equity stake post-transaction and open offer. Dr. B.S. Ajaikumar will be a co-promoter. CVC will be a public shareholder
    *   **Focus on Precision Oncology:** Emphasis on personalized treatment, genomics, proteomics, research, and academics.
    *   Restructuring of diagnostic business, Triesta.
*   **New Products/Services/Markets:**
    *   Continued focus on expanding the hub-and-spoke model with infusion clinics.
*   **Operational Changes:**
    *   Dr. B.S. Ajaikumar will transition from Executive Chairman to Chairman of the Board, focusing on clinical excellence, research, and academics, with limited involvement in daily operations.
    *   Consolidation of MG Hospital operations in Vizag.
    *   Strengthening the andrology department at Milann.
*   **Ongoing/Completed Projects:**
    *   Two new brownfield centers in Bangalore are expected to be operationalized in FY '26.

### Market & Competitive Landscape

*   **Industry Trends:**
    *   Oncology is growing rapidly in India.
    *   Indian genomics is different from Caucasians, necessitating localized treatment approaches.
    *   Infertility is becoming a major issue in India.
    *   Medical Tourism impacted due to the Indian government restricting medical visas.
*   **Competitive Positioning:**
    *   HCG positions itself as a leader in comprehensive cancer care.
    *   Focus on asset-light model for efficient expansion.
*   **Market Challenges/Opportunities:**
    *   **Opportunity:** Growing demand for oncology services in India.
    *   **Opportunity:** Potential for mergers and acquisitions.
    *   **Challenge:** Geopolitical issues impacting international business, specifically mentioned for the South Mumbai center.
*   **Market Share/Positioning:**
    *   Indicates growth in market share across regions.

### Risk Factors & Challenges

*   **Concerns/Challenges:**
    *   Seasonality impacting Q3 performance.
    *   Geopolitical issues impacting international patient flow, particularly from Bangladesh.
    *   Decline in Milann revenue due to increased competition.
    *   Operational losses from new centers.
*   **Regulatory Issues:**
    *   Mention of regulatory processes related to the KKR acquisition and open offer.
*   **Operational Constraints:**
    *   Mention of subdued international business
*   **Market Uncertainties:**
    *   Uncertainty regarding the open offer participation.

### Forward-Looking Statements

*   **Outlook and Projections:**
    *   Expect continued strong growth in emerging centers.
    *   Expect recovery in international business by the upcoming quarter.
    *   Anticipates normalization of modality mix and revenue scale-up, improving margins.
*   **Commitments/Targets:**
    *   Focus on long-term growth with KKR.
    *   Aim to minimize cancer recurrence.
    *   South Mumbai center expected to break even by Q1 of next financial year.
*   **Planned Investments:**
    *   Continued investment in medical infrastructure, specialized treatments, and clinical talent.
    *   Capital expenditure of approximately INR275-280 crores for FY25 and FY26.
*   **Sentiment:**
    *   Positive sentiment about future performance, and "gung-ho about the potential of the organization".

### Q&A Insights

*   **Most Pressing Analyst Questions:**
    *   Clarification on the shareholding structure post-acquisition.
    *   Dr. Ajaikumar's role in the organization after the transition.
    *   Margin trajectory and impact of new centers.
    *   Growth rate of established centers.
    *   Performance and turnaround plans for Mumbai centers (Borivali and South Mumbai).
    *   Impact of the KKR acquisition on business plans.
    *   Outlook on international patient business.
    *   Capex guidance and debt levels.
    *   Strategy for Milann.
*   **Challenging Questions & Responses:**
    *   **Debt Levels:** Management stated they are comfortable with current debt levels and banking covenants.
    *   **Milann's Performance:** Management acknowledged the decline but expressed optimism about a turnaround due to new strategies and leadership changes.
    *   **Y-o-Y Margin Pressure in Established Centers:** Management attributed this to lower operating leverage due to revenue reduction and a higher proportion of pharmacy business, expecting normalization in Q4.
*   **Indirect Answers:**
    *   Specific details on the timeline of the open offer were deferred, citing regulatory processes.
    *   Details about profit/loss contribution on the PBT level for MG Hospital was not disclosed.
*   **New Information:**
    *   Confirmation that Dr. Ajaikumar will be a co-promoter with KKR.
    *   CVC will be classified as a public shareholder.
    *   South Mumbai center's EBITDA loss for FY '25 is estimated at INR 10-12 crores.
    *   Andrology focus as a growth driver for Milann.

### Management Tone & Sentiment

*   **Overall Tone:** The overall tone is very confident and optimistic. Management repeatedly emphasizes the company's strong performance, growth potential, and strategic direction.
*   **Changes in Language:** No significant changes were noted compared to hypothetical previous calls, as this is the first analysis. However, the language is strongly positive, emphasizing achievements and future plans.
*   **Confidence/Concern:**
    *   **Confident:** Growth prospects, clinical excellence, operational efficiency, new partnerships, and market leadership.
    *   **Concerned (but optimistic):** Milann's performance, although management is actively addressing the challenges. Impact of geopolitical issues on international business, but expect a quick recovery.

### Key Takeaways

1.  **Strong Financial Performance:** HCG reported its highest-ever quarterly revenue and solid YoY growth, demonstrating resilience despite seasonality.
2.  **Strategic Shift:** The KKR acquisition marks a significant strategic shift, with Dr. Ajaikumar focusing on clinical excellence and research, while KKR takes a majority stake.
3.  **Growth Focus:** HCG is committed to both organic growth (existing centers, brownfield expansions) and potential inorganic growth (mergers and acquisitions).
4.  **Turnaround Potential:** While Milann faces challenges, management is optimistic about a turnaround. The South Mumbai center is also projected to break even soon.
5.  **Positive Outlook:** Management is highly confident about the future, expecting continued growth, margin expansion, and a strong performance in the coming quarters.
6.  International business is expected to rebound.
7.  Effective tax rate is low (3%) due to the recognision of a deferred tax.



{{< rawhtml >}}

<div class="button-container">    
    <a href="https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8b81c48-e01f-48a4-98c4-b270b8711902.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Transcript
    </a>
</div>
    
{{< /rawhtml >}}
